Evidence map›Paper›PMID 29343411›Full record

ArticleVaccine2018

Consequence of enhanced LC3-trafficking for a live, attenuated M. tuberculosis vaccine.

Stefan Köster, Thais Klevorn, Kadamba Papavinasasundaram, Christopher M Sassetti, Cynthia Portal-Celhay, Jennifer A Philips

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. LC3-Associated Phagocytosis in Bacterial Infection.Pathogens (Basel, Switzerland) · 2022
    Review
  4. Review
  5. Review
  6. Frontiers in cellular and infection microbiology · 2021
    Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Stefan KösterDivision of Infectious Diseases, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA.
Thais KlevornDivision of Infectious Diseases, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA.
Kadamba PapavinasasundaramDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Christopher M SassettiDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Cynthia Portal-CelhayDivision of Infectious Diseases, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA.
Jennifer A PhilipsDivision of Infectious Diseases, Department of Medicine, Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: philips.j.a@wustl.edu.
New York University · USUniversity of Massachusetts Chan Medical School · USWashington University in St. Louis · US

Funding

Mechanisms of Innate Immune Evasion by Mycobacterium TuberculosisR01AI130454 · NIAID · WASHINGTON UNIVERSITY · PI JENNIFER A PHILIPS · 2017 to 2026
$5.9M
Chromosome 17q, allergic inflammation, and remodelingR01AI107779 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROIDE, DAVID H · 2013 to 2024
$4.7M
Tuberculosis Pathogenesis and Drug ResponseR01AI064282 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SASSETTI, CHRISTOPHER M · 2007 to 2017
$3.9M
Molecular mechanism of T cell evasion by Mycobacterium tuberculosisK08AI119150 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PORTAL CELHAY, CYNTHIA · 2015 to 2018
$773k
NIAID NIH HHS K08 AI119150NIAID NIH HHS R01 AI064282NIAID NIH HHS R01 AI107779NIAID NIH HHS R01 AI130454
6 · The paper itself

Abstract

Development of a new vaccine against tuberculosis is urgently needed. Recent work has demonstrated that two related LC3-associated trafficking pathways, autophagy and LC3-associated phagocytosis (LAP), enhance antigen presentation and might play a role in vaccine efficacy. Mycobacterium tuberculosis inhibits both LC3-trafficking pathways. Moreover, the vaccine strain, BCG, induces even less LC3-trafficking than M. tuberculosis, which may help explain its limited efficacy. To determine whether enhanced LC3-trafficking can improve efficacy of a live, attenuated M. tuberculosis vaccine, we took advantage of our recent finding that the bacterial virulence factor CpsA inhibits LAP. When we deleted cpsA in the mc

Indexed as

AnimalsAntigen PresentationBCG VaccineHumansImmunizationImmunogenicity, VaccineMacrophagesMiceMutationMycobacterium tuberculosisPhagocytosisTuberculosisTuberculosis VaccinesVaccines, AttenuatedBCG VaccineTuberculosis VaccinesVaccines, AttenuatedAutophagyAuxotrophBCGInnate immunityLC3-associated phagocytosisLive attenuated vaccineTuberculosis

Identifiers

PMID29343411
PMCPMC5930169
OpenAlexW2782639424

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.